/

Società

Mi

Non verificato

MiraDx

Di cosa scriviamo

BiotecnologiaIndustriaOncologiaSaluteScienza

5 comunicati stampa

Guarda tutti i comunicati

18/12/2025

Industria

Oncologia

Salute

Biotecnologia

Scienza

Farmaceutica

New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy

Fonte

Emittente

1.00

0

01/10/2025

Biotecnologia

Salute

Medicina nucleare

Oncologia

Attrezzature medico-sanitarie

Scienza

Vetrine/Shopping

Industria

MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy

Fonte

Emittente

1.00

0

26/09/2025

Eventi

Industria

Biotecnologia

Salute

Vetrine/Shopping

Medicina nucleare

Biologia

Oncologia

Università

Scienza

Attrezzature medico-sanitarie

Scuola/Istruzione

Medicina - Varie

MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT Toxicity Can Safely Receive Other Radiation Regimens

Fonte

Emittente

1.00

0

22/05/2025

Mercato del lavoro

Eventi

Industria

Scienza

Biotecnologia

Oncologia

Salute

Attrezzature medico-sanitarie

Medicina - Varie

MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 that Highlights the Role of MicroRNA-based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related Outcomes

Fonte

Emittente

1.00

0

07/04/2025

Industria

Scienza

Biotecnologia

Oncologia

Salute

Attrezzature medico-sanitarie

Medicina - Varie

MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0